Ask AI

Multiple Myeloma

Share

Program Content

Activities

DURGA 1
DURGA-1: Phase Ib/II Study of AZD0120, a BCMA/CD19 Dual-Targeting CAR T-Cell Therapy, in R/R MM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2025

CAMMA 1 Updated Analysis
CAMMA 1: Updated Safety, Efficacy, and Biomarker Analyses From Phase I Study of Cevostamab + Pomalidomide + Dexamethasone in BCMA1-Naive RRMM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients.

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

BeOne Medicines

Genentech

Geron Corporation

Incyte

Johnson & Johnson

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner